Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

This paper deals with thyroid disease that can occur after treatment with alemtuzumab (humanized monoclonal anti-CD52) for relapsing–remitting multiple sclerosis (MS). The 5-year incidence of thyroid adverse events in phase 3 clinical trials is up to 40.7%. In most cases, the thyroid dysfunction is...

Descripción completa

Detalles Bibliográficos
Autores principales: Decallonne, Brigitte, Bartholomé, Emmanuel, Delvaux, Valérie, D’haeseleer, Miguel, El Sankari, Souraya, Seeldrayers, Pierrette, Van Wijmeersch, Bart, Daumerie, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Consensus paper and Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971042/
https://www.ncbi.nlm.nih.gov/pubmed/29372482
http://dx.doi.org/10.1007/s13760-018-0883-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971042/
https://www.ncbi.nlm.nih.gov/pubmed/29372482
http://dx.doi.org/10.1007/s13760-018-0883-2

Ejemplares similares